{"url_path":"/sec/cbio/8-k/2026-07-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1253689/0001628280-26-048347-index.html","accession_number":"0001628280-26-048347","cik":"0001253689","ticker":"CBIO","issuer_name":"CRESCENT BIOPHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1253689/0001628280-26-048347-index.html","primary_entity_key":"0001253689","primary_entity_name":"CRESCENT BIOPHARMA, INC."},"word_count":149,"has_tables":true,"body_markdown":"Item 9.01        Financial Statements and Exhibits.\n\n(d)Exhibits\n\nExhibit No.Description\n\n1.1\n[Underwriting Agreement, dated July 14, 2026, by and among Crescent Biopharma, Inc. and Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein](exhibit11underwritingagree.htm)\n\n4.1\n[Form of Pre-Funded Warrant](exhibit41formofpre-fundedw.htm)\n\n5.1\n[Opinion of Walkers (Cayman) LLP](exhibit51walkersopiniondeal.htm)\n\n5.2\n[Opinion of Latham & Watkins LLP](exhibit52lathamopiniondeal.htm)\n\n23.1\n[Consent of Walkers (Cayman) LLP (included in Exhibit 5.1)](exhibit51walkersopiniondeal.htm)\n\n23.2\n[Consent of Latham & Watkins LLP (included in Exhibit 5.2)](exhibit52lathamopiniondeal.htm)\n\n99.1\n[Press Release, dated July 14, 2026](exhibit991launchpressrelea.htm)\n\n99.2\n[Press Release, dated July 14, 2026](exhibit992pricingpressrele.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nCRESCENT BIOPHARMA, INC.\n\nDate: July 15, 2026By:/s/ Joshua Brumm\n\nName:Joshua Brumm\n\nTitle:Chief Executive Officer"}